The DNPEP Knockout HeLa Polyclonal Cells product provides researchers with a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa human epithelial cell line. This pooled population harbors targeted disruption of the DNPEP gene, generating a loss-of-function model suitable for functional genomics studies. The polyclonal format maintains cellular heterogeneity, enabling robust analysis of gene function without the clonal artifacts that can arise in single-cell-derived lines. This knockout model is designed for use in a broad range of assays investigating the role of DNPEP in protein turnover, peptide hormone processing, and disease-related pathways.
The host cell line, HeLa, is an immortalized cervical adenocarcinoma cell line integrated with human papillomavirus type 18 (HPV18) sequences. Widely regarded as a workhorse model in cancer biology and general molecular biology, HeLa cells exhibit an adherent epithelial morphology and rapid proliferation. Their well-characterized genetic background and extensive experimental history make them an ideal chassis for gene knockout studies. The integration of HPV18 oncogenes E6 and E7 disrupts p53 and Rb tumor suppressor pathways, providing a unique context for investigating oncogenic mechanisms and therapeutic responses.
DNPEP (aspartyl aminopeptidase) encodes a zinc-dependent metalloprotease that specifically removes N-terminal aspartate and glutamate residues from peptide substrates. This activity is central to protein catabolism and the maturation or inactivation of bioactive peptides. DNPEP functions downstream of proteolytic signals and substrate availability, with interactions documented with other aminopeptidases such as LAP3 and ANPEP. Notably, DNPEP participates in the renin-angiotensin system by processing angiotensin peptides??generated through the sequential actions of AGT, REN, and ACE??to produce active metabolites that signal through the AGTR1 receptor. Disruption of DNPEP thus alters the balance of angiotensin metabolites, offering a tool to dissect this signaling axis.
In the HeLa carcinoma background, DNPEP knockout provides a valuable system for studying the intersection of peptide processing and cancer cell biology. Since HeLa cells harbor HPV-driven transformation pathways, the DNPEP loss-of-function model may reveal contributions of aminopeptidase activity to tumor cell proliferation, survival, or peptide hormone-mediated signaling. Additionally, given the role of the renin-angiotensin system in hypertension and the expression of its components in several cancers, this model is relevant for exploring how angiotensin metabolite profiles influence cellular behavior in a cancerous context.
Research applications include functional genomics, peptide processing studies, cancer cell biology, and drug screening. The knockout cell population can be validated by western blotting, RT-qPCR, and immunofluorescence to confirm DNPEP disruption, and assayed using aminopeptidase activity assays, angiotensin processing assays, and cell proliferation assays. These cells are suitable for investigating the effects of DNPEP loss on substrate cleavage dynamics and downstream signaling. For further information on validation data, availability, or custom inquiries, please contact Ascent Research.
